The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, AbbVie buys ImmunoGen for a cool $10B and scores a win with Teliso-V as ADC momentum continues to build.

Plus, the FDA investigates malignacies linked to CAR-T.

BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.